- Home
- ZS vs ROIV Comparison
ZS vs ROIV Comparison
Compare ZS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZS | ROIV |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 28.7B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ZS | ROIV |
|---|---|---|
| Price | $207.86 | $33.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 46 | 13 |
| Target Price | ★ $233.72 | $48.27 |
| AVG Volume (30 Days) | 2.8M | ★ 6.4M |
| Earning Date | 11-24-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $17.27 | $530.75 |
| Revenue Next Year | $16.48 | $685.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $114.63 | $17.28 |
| 52 Week High | $336.99 | $42.50 |
Technical Indicators
Market Signals| Indicator | ZS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 37.60 |
| Support Level | $204.67 | $33.15 |
| Resistance Level | $216.97 | $37.59 |
| Average True Range (ATR) | 9.12 | 1.07 |
| MACD | -0.49 | -0.26 |
| Stochastic Oscillator | 31.87 | 13.23 |
Price Performance
Historical ComparisonAbout ZS Zscaler Inc.
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.